Preliminary research results, 2026.
~84% PTSD Remission at end of retreat across two cohorts of Israeli combat soldiers.
A multi-modal retreat combining psychedelic-assisted therapy, functional medicine, somatic therapy, strength training, organic nutrition, and nature immersion — delivered to 26 combat soldiers across two cohorts.
CUMULATIVE FINDINGS | N=26
26
Combat soldiers treated.
~84%
PTSD remission. (end of retreat)
~78%
Cohort i durability. (1-month)
4
Clinical domain improved.
Cohort II protocol: MDMA, psilocybin (x2), and ayahuasca – substance selection guided by clinic asessment. · PRELIMINARY DATA, NOT YET PEER-REVIEWED.
N = 26 Combat soldiers · 2 Cohorts · Dec 2025 + Feb 2026 · Preliminary Data
What our protocol delivered:
~84%
PTSD remission. (end of retreat)
~77%
Depression improvement (mean reduction)
~73%
Insomnia improvement (mean reduction)
RELIMINARY · NOT YET PEER-REVIEWED · PCL-5 (≥33) · PHQ-9 (≥10) · GAD-7 (≥8) · END OF RETREAT · COHORT I ALSO MEASURED AT 1-MONTH FOLLOW-U
Of 26 combat soldiers who arrived with PTSD, 21 are below threshold at end of retreat.
2 Cohorts - 26 Soldiers
COHORT I
December 2025 · N = 12 · 3 sessions
Before
12 of 12 met PTSD criteria
After
10 of 12 below threshold · 83%
COHORT II
December 2025 · N = 12 · 3 sessions
Before
12 of 12 met PTSD criteria
After
10 of 12 below threshold · 83%
CUMULATIVE: 21 OF 26 BELOW THRESHOLD (~81%) · PCL-5 ≥33 CUTOFF · END OF RETREAT · 1 COHORT II PARTICIPANT WITH MISSING DATA · PRELIMINARY